China Approves First Domestic Monkeypox Virus Nucleic Acid Test Kit

On August 19, the National Medical Products Administration approved Daan Gene's Monkeypox Virus Nucleic Acid Test Kit (Fluorescent PCR Method), marking the first monkeypox virus test product approved for marketing in China.

 

This approval follows the World Health Organization's August 14 announcement declaring the escalating monkeypox outbreaks in several African countries as a 'public health emergency of international concern.' This is the second time in two years that WHO has issued its highest level of alert for monkeypox. In response, China's General Administration of Customs announced measures on August 15 to prevent the monkeypox epidemic from entering the country.

 

 

Sansure Releases the Interim Report with Total Operating Revenue Up 67.63% YOY

 

On August 19, Sansure Biotech released its interim report for the first half year of 2024. The company reported total operating revenue of 717 million yuan, marking a 67.63% increase year-on-year. Net profit attributable to shareholders reached 157 million yuan, a 70.93% rise. After accounting for extraordinary gains and losses, net profit stood at 121 million yuan, a staggering 288.48% increase.

 

Sansure Biotech has continued to implement the innovation-driven strategy, strengthened the platform and internationalization strategy, and actively grasped the opportunities of counter-cyclical development, and has made great progress in the technology, products and market layout in many key areas, such as respiratory, maternal and child and has gradually entered the phase of volume growth.

 

 

Wondfo reports 9.93% Growth in Non-Deductible Net Profit for H1 2024

 

On the evening of August 13, Wondfo Biotech released its 2024 half-year report, showing steady growth. The company reported total operating revenue of 1.575 billion yuan for the first half of the year, a 5.82% year-on-year increase. Net profit attributable to shareholders reached 356 million yuan, up 6.37%, with non-deductible net profit rising 9.93% to 325 million yuan. Net operating cash flow saw a substantial increase of 311.02%, reaching 200 million yuan.

 

Wondfo Biotech's infectious disease business generated 481 million yuan in revenue, a 12.50% increase year-on-year. The chronic disease management testing segment earned 762 million yuan, up 6.14%, while the drug (substance abuse) testing business brought in 139 million yuan. The eugenics testing business achieved 157 million yuan in revenue, marking a 16.92% year-on-year increase.

 

The company continues to prioritize research and development efficiency. In the first half of the year, Wondfo Biotech invested 217 million yuan in R&D, representing 13.75% of total revenue. This investment resulted in 20 new authorized invention patents, 27 new product registration certificates, and progress on 68 new product developments and improvements.

 

 

AmoyDx 2024 H1: Results Meet Expectations, International Business Shows Rapid Growth

 

In the first half of 2024, AmoyDx reported operating income of 543 million yuan, a year-on-year increase of 18.38%. The company achieved a net profit of 144 million yuan, up 13.49%, while non-deductible net profit rose 20.72% to 132 million yuan.

 

AmoyDx continued to enhance its precision medicine technology platform, particularly in oncology diagnostics, with an R&D investment of 106 million yuan, a 15.62% year-on-year increase, representing 19.56% of total revenue.

 

The company's companion diagnostic collaborations expanded significantly, particularly with leading domestic and global pharmaceutical companies. This has reinforced the company's reputation for product quality and brand recognition. Domestic sales reached 413 million yuan, a 16.02% increase year-on-year, while international sales and business with pharmaceutical companies generated 130 million yuan, reflecting a 26.51% year-on-year growth.

 

 

Novogene: Enhanced Global Service Capability Drives Increased Overseas Revenue in H1 2024

 

In the first half of 2024, Novogene reported operating revenue of 997 million yuan, reflecting a 7.18% year-on-year increase. The company's net profit attributable to shareholders reached 78 million yuan, up 3.86%, while non-deductible net profit rose 12.92% to 66 million yuan.

 

Overseas business, including revenue from Hong Kong, Macao, Taiwan, and other international markets, contributed 501 million yuan, an 8.09% year-on-year increase, accounting for 50.26% of total revenue. Revenue from mainland China amounted to 496 million yuan, up 6.27%.

 

Among business segments, life science basic research services experienced the fastest growth, generating 343 million yuan in revenue. Sequencing platform services brought in 487 million yuan, and medical research and technology services contributed 139 million yuan.